C4 Therapeutics, Inc. (CCCC)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
3.85 USD
-0.25
(-6.098%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.91 +0.06 (1.538%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:36 a.m. EDT
The long-term investment case is severely compromised by a brutal four-year trajectory where the stock has lost nearly 94% of its value. While the company boasts a fortress balance sheet with minimal debt and strong gross margins, the market has punished the business with a structural decline, evidenced by three consecutive years of negative annual returns. This persistent underperformance suggests the market views the current management or pipeline execution as fundamentally flawed, rendering the attractive valuation metrics a 'value trap' rather than a bargain. The short-term outlook remains murky; while the stock recently rallied off its lows, the statistical forecast offers no directional clarity, and the heavy options positioning indicates traders are waiting for a specific catalyst rather than betting on organic recovery. Without a clear turnaround in the underlying business quality, the risk of further deterioration outweighs the potential for a rebound. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099113 |
| AutoARIMA | 0.113301 |
| AutoETS | 0.113558 |
| MSTL | 0.122720 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.285 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.995 |
| Revenue per Share | 0.314 |
| Market Cap | 473,646,752 |
| Forward P/E | -3.86 |
| Beta | 2.95 |
| Profit Margins | -289.44% |
| Website | https://www.c4therapeutics.com |
As of Aug. 22, 2026, 2:36 a.m. EDT: Speculators are positioning for a binary event rather than steady appreciation. There is heavy open interest in out-of-the-money calls (strikes $6.00 and $9.00) expiring in late 2026 and early 2027, suggesting a bet on a massive price surge or successful clinical milestone. Conversely, significant put volume exists at lower strikes ($2.00, $3.00) for near-term expirations, indicating a hedge against continued volatility or failure. The implied volatility skew is extreme, with deep OTM calls priced at a premium relative to ATM options, reflecting high uncertainty about the stock's ability to recover from its multi-year decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6334661 |
| Address1 | 490 Arsenal Way |
| Address2 | Suite120 |
| All Time High | 51.21 |
| All Time Low | 1.06 |
| Ask | 5.06 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,453,540 |
| Average Daily Volume3 Month | 3,053,956 |
| Average Volume | 3,053,956 |
| Average Volume10Days | 2,453,540 |
| Beta | 2.946 |
| Bid | 3.89 |
| Bid Size | 1 |
| Book Value | 2.012 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.85 |
| Current Ratio | 5.449 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.1 |
| Day Low | 3.83 |
| Debt To Equity | 22.995 |
| Display Name | C4 Therapeutics |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -99,448,000 |
| Ebitda Margins | -2.83821 |
| Enterprise To Ebitda | -2.784 |
| Enterprise To Revenue | 7.901 |
| Enterprise Value | 276,841,760 |
| Eps Current Year | -0.885 |
| Eps Forward | -0.9975 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.9589 |
| Fifty Day Average Change | -0.10890007 |
| Fifty Day Average Change Percent | -0.027507659 |
| Fifty Two Week Change Percent | 63.34661 |
| Fifty Two Week High | 5.17 |
| Fifty Two Week High Change | -1.3200002 |
| Fifty Two Week High Change Percent | -0.25531918 |
| Fifty Two Week Low | 1.69 |
| Fifty Two Week Low Change | 2.1599998 |
| Fifty Two Week Low Change Percent | 1.2781063 |
| Fifty Two Week Range | 1.69 - 5.17 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,645,400,000 |
| Float Shares | 94,515,291 |
| Forward Eps | -0.9975 |
| Forward P E | -3.859649 |
| Free Cashflow | -43,664,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 104 |
| Fullday Change | -0.25 |
| Fullday Change Percent | -6.09756 |
| Fullday Price | 3.9092 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.86344004 |
| Gross Profits | 30,254,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00835 |
| Held Percent Institutions | 1.02023 |
| Implied Shares Outstanding | 123,025,136 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name | C4 Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 473,646,752 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_321572356 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,416,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 503,787,931 |
| Number Of Analyst Opinions | 6 |
| Open | 4.07 |
| Operating Cashflow | -84,870,000 |
| Operating Margins | -3.9787703 |
| Payout Ratio | 0.0 |
| Phone | 617 231 0700 |
| Post Market Change | 0.05920005 |
| Post Market Change Percent | 1.5376636 |
| Post Market Price | 3.9092 |
| Post Market Time | 1,787,961,554 |
| Previous Close | 4.1 |
| Price Eps Current Year | -4.350282 |
| Price Hint | 4 |
| Price To Book | 1.9135188 |
| Price To Sales Trailing12 Months | 13.517702 |
| Profit Margins | -2.89437 |
| Quick Ratio | 5.285 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.25 |
| Regular Market Change Percent | -6.09756 |
| Regular Market Day High | 4.1 |
| Regular Market Day Low | 3.83 |
| Regular Market Day Range | 3.83 - 4.1 |
| Regular Market Open | 4.07 |
| Regular Market Previous Close | 4.1 |
| Regular Market Price | 3.85 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,823,145 |
| Return On Assets | -0.19253999 |
| Return On Equity | -0.48141 |
| Revenue Growth | 0.028 |
| Revenue Per Share | 0.314 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 123,025,136 |
| Shares Percent Shares Out | 0.2768 |
| Shares Short | 34,048,321 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 23,815,010 |
| Short Name | C4 Therapeutics, Inc. |
| Short Percent Of Float | 0.2784 |
| Short Ratio | 12.57 |
| Source Interval | 15 |
| State | MA |
| Symbol | CCCC |
| Target High Price | 30.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 13.33333 |
| Target Median Price | 11.0 |
| Total Cash | 253,663,008 |
| Total Cash Per Share | 2.062 |
| Total Debt | 56,858,000 |
| Total Revenue | 35,039,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.004425 |
| Two Hundred Day Average Change | 0.84557486 |
| Two Hundred Day Average Change Percent | 0.28144315 |
| Type Disp | Equity |
| Volume | 1,823,145 |
| Website | https://www.c4therapeutics.com |
| Zip | 2,472 |